Gyre Therapeutics (NASDAQ:GYRE) Trading 8.2% Higher – Still a Buy?

Gyre Therapeutics, Inc. (NASDAQ:GYRE)’s stock price shot up 8.2% on Monday . The company traded as high as $8.86 and last traded at $8.9150. 77,539 shares traded hands during mid-day trading, an increase of 5% from the average session volume of 73,646 shares. The stock had previously closed at $8.24.

Wall Street Analyst Weigh In

Several research firms have commented on GYRE. Weiss Ratings reissued a “sell (d)” rating on shares of Gyre Therapeutics in a research note on Thursday, January 22nd. Wall Street Zen raised shares of Gyre Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, November 15th. Finally, Zacks Research raised shares of Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday, November 14th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $17.00.

Gyre Therapeutics Price Performance

The firm’s 50 day moving average is $7.82 and its 200 day moving average is $7.78. The company has a market capitalization of $797.61 million, a PE ratio of 276.09 and a beta of 1.97.

Institutional Trading of Gyre Therapeutics

Large investors have recently modified their holdings of the business. SBI Securities Co. Ltd. raised its position in Gyre Therapeutics by 87.9% during the 2nd quarter. SBI Securities Co. Ltd. now owns 232,299 shares of the company’s stock valued at $1,707,000 after purchasing an additional 108,670 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Gyre Therapeutics by 28.6% during the second quarter. Geode Capital Management LLC now owns 401,709 shares of the company’s stock valued at $2,953,000 after buying an additional 89,390 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in shares of Gyre Therapeutics by 37.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 169,158 shares of the company’s stock valued at $1,194,000 after acquiring an additional 45,772 shares in the last quarter. Millennium Management LLC purchased a new stake in Gyre Therapeutics in the third quarter worth $267,000. Finally, State Street Corp boosted its holdings in Gyre Therapeutics by 10.7% in the fourth quarter. State Street Corp now owns 202,225 shares of the company’s stock valued at $1,428,000 after acquiring an additional 19,472 shares in the last quarter. 23.99% of the stock is owned by institutional investors.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.